QIAGEN Surpasses Q1 2025 Outlook, Raises Full-Year EPS Forecast QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced strong preliminary results for the first quarter of 2025, surpassing both…
Sentynl Therapeutics Unveils First Clinical Evidence Supporting NULIBRY® for Molybdenum Cofactor Deficiency Type A Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd., has announced the…
ABEC Unveils Single-Use Bioreactor for Cell Therapy Manufacturing ABEC, a global leader in engineered solutions for biotechnology manufacturing, has introduced its Advanced Therapy Bioreactor (ATB™), a groundbreaking platform designed to…
GeneDx Expands Exome and Genome Testing to Include Inborn Errors of Immunity GeneDx (Nasdaq: WGS), a leader in genomic diagnostics, has announced the expansion of its commercial focus to include…
Utah Fertility Center Hires Dr. Erica Louden and Dr. Melinda Henne Ivy Fertility, a global network of renowned fertility clinics, is excited to announce the addition of Dr. Erica Louden…
AGC Biologics Launches Cellular and Genetic Technologies Division to Boost Nine Market-Approved Products AGC Biologics, a leading Contract Development and Manufacturing Organization (CDMO), has announced the creation of its new…
ELIQUENT Life Sciences Acquires Truliant Consulting to Expand Pharmacovigilance Platform ELIQUENT Life Sciences, a global leader in regulatory, quality, and safety consulting, has announced the strategic acquisition of Truliant Consulting,…
Johnson & Johnson Completes Intra-Cellular Therapies Acquisition to Strengthen Neuroscience Leadership Johnson & Johnson (NYSE: JNJ) has officially completed its acquisition of Intra-Cellular Therapies, Inc., further strengthening its position in…
Sydnexis Receives Positive CHMP Opinion for SYD-101 in Pediatric Myopia Sydnexis, Inc., a pre-commercial biopharmaceutical company, has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Tris Pharma to Present Data on Cebranopadol at AAPM PainConnect Meeting Tris Pharma, Inc., a biopharmaceutical company focused on commercial-stage development, has announced its participation in the upcoming 2025 American…
Corcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint Corcept Therapeutics Incorporated (NASDAQ: CORT), a company focused on developing treatments for serious endocrinologic, oncologic, metabolic,…
ABEC Launches Breakthrough Single-Use Bioreactor Technology for Cell Therapy ABEC, a global leader in engineered solutions and services for biotech manufacturing, has unveiled its Advanced Therapy Bioreactor (ATB™), a groundbreaking…